Journal of the American Academy of Child & Adolescent Psychiatry
Volume 46, Issue 10 , Pages 1375-1379, October 2007

Pharmacological Management of Bipolar Disorder in a Youth With Diabetes

Dr. DelBello is with the University of Cincinnati College of Medicine; Dr. Correll is with the Zucker Hillside Hospital, North Shore-Long Island Jewish Health System, and the Albert Einstein College of Medicine; Dr. G. Carlson is with the SUNY-Stony Brook School of Medicine; Dr. H. Carlson is with SUNY-Stony Brook; and Dr. Kratochvil is with the University of Nebraska Medical Center

Accepted 30 May 2007.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 12.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

 This is a case vignette created to exemplify a complex clinical problem and does not refer to any specific patient.This column aims to discuss practical approaches to everyday issues in pediatric pharmacotherapy. The cases and discussions specifically target aspects of clinical care related to psychopharmacology for which we do not have adequate applicable controlled trials. Given the need to address symptoms in youths with complex, severe, and comorbid disorders, recommendations are likely to be off-label from the perspective of the U.S. Food and Drug Administration. We fully appreciate that for virtually all disorders, medication is only one aspect of comprehensive care. This column focuses primarily on psychopharmacological management. Although it is important that clinicians address psychosocial issues in the evaluation and treatment of their patients, such discussion is beyond the specific scope of this feature. These are not meant to be practice guidelines, but rather examples of thought processes that may go into pharmacotherapy decision making.Disclosure: Dr. DelBello has served as a consultant to or a speaker for or received research funding from AstraZeneca, Abbott, Eli Lilly, Pfizer, Shire, and Janssen. Dr. Correll has been a consultant to AstraZeneca, Bristol-Myers Squibb/Otsuka, Eli Lilly, Solvay, and Intracellular Therapies; an advisor to Bristol-Myers Squibb/Otsuka and Eli Lilly; and a lecturer for AstraZeneca and Bristol-Myers Squibb/Otsuka. Dr.G. Carlson has received research grants from Janssen, Otsuka, Bristol-Myers Squibb, Sanofi-Aventis, and Eli Lilly, and has been an advisor to Janssen, Otsuka, Eli Lilly, and Shire. Dr. H. Carlson has served as a consultant to Otsuka. Dr. Kratochvil receives grant support from Eli Lilly, McNeil, Shire, Abbott, and Cephalon; is a consultant to Eli Lilly, Cephalon, AstraZeneca, Abbott, and Pfizer; and is a member of the Eli Lilly speakers' bureau. Dr. Kratochvil receives study drug for an NIMH-funded study from Eli Lilly.

PII: S0890-8567(09)61857-8

doi:10.1097/chi.0b013e31813c69c9

Journal of the American Academy of Child & Adolescent Psychiatry
Volume 46, Issue 10 , Pages 1375-1379, October 2007

Article Tools